Fig. 6

The anti-GBM effect of DCPS inhibition was mediated through reducing STAT5B expression

(a) GBM cell lines with STAT5B overexpression or vector expression were treated with various concentrations of RG3039 or DMSO for 72 h. The IC50 of RG3039 was analyzed by CCK-8 assay (n = 3)

(b) Quantification of the ratio of Annexin-V-positive cells in apoptosis assays (see Figure S2b for details) in GBM cell lines with STAT5B overexpression or vector expression treated with RG3039 (6 µM) to that of cells treated with DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, **, p < 0.01, ***, p < 0.001

(c) Representative images of colony formation assays in GBM cell lines with STAT5B overexpression or vector expression treated with various concentrations of RG3039 or DMSO for 14 days

(d) Quantification of the ratio of colony formation of GBM cells with STAT5B overexpression or vector treated with RG3039 to cells treated with DMSO (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, *, p < 0.05, ***, p < 0.001

(e) Schematic diagram summarizing that RG3039 inhibits DCPS regulating the expression of STAT5B, which plays an essential role in tumor progression